Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

Symptoms of myasthenia gravis (MG) can shift markedly from one week to the next, but the clinic visits that guide treatment often sit months apart, leaving long stretches of a patient's disease course unobserved. A German randomized controlled study tested whether a smartphone-and-sensor platform could close that gap and found that frequent remote assessments surfaced meaningful symptom variability that standard visits would likely miss.¹

The Stakes of Undetected Worsening in Myasthenia Gravis

MG is a rare autoimmune disorder marked by fluctuating, fatigable muscle weakness that can escalate into life-threatening respiratory crises, and that instability carries real consequences. A targeted literature review reported that 13% to 23% of patients with MG experienced a myasthenic crisis, a failure of the respiratory muscles that can be fatal, and identified hospitalization and treatment of exacerbations or crises as leading drivers of the condition's direct medical costs.² Patients also faced an elevated risk of hospitalization, particularly within the first year after diagnosis. Because conventional care relies on brief, infrequent in-person assessments, worsening that develops between appointments can go undetected until it becomes urgent.

Tracking Myasthenia Gravis Symptoms Week to Week

Researchers enrolled 45 people with MG and randomized them 2:1 to remote monitoring plus standard care (n = 30) or standard care alone (n = 15) over a 12-week period.¹ Participants in the intervention group used the MyaLink app to complete patient-reported outcome measures, transmitted spirometry and wearable data through connected devices, and messaged their physicians through a secure chat, while physicians reviewed the incoming data through a web portal and conducted 2 telemedical check-ups. The cohort had a median age of 48.0 years (IQR, 42.0-58.0), was 73.3% female, and had a median disease duration of 5 years, with comorbidities present in 82.2% of participants.

Across the 12 weeks, clinical scores fluctuated considerably within individuals even though end-of-study comparisons showed no statistically significant differences between the intervention and control groups. The variability was most apparent among participants who experienced an MG-related hospitalization or exacerbation (H&E subgroup), who showed wider swings in daily-living scores, with a mean MG-ADL range of 5.8 points compared with 2.6 points in participants without such events. The pattern extended to communication, as 60% of the H&E subgroup sent between 11 and 40 messages during the study, compared with 40% of the remaining participants.

Flagging the Patients Most Likely to Deteriorate

The subgroup that deteriorated also drew more clinical attention. Steroid doses were adjusted in 40% of the H&E subgroup and in none of the participants without hospitalizations or exacerbations, and 93.3% of the H&E subgroup received at least 1 physician-initiated intervention during a telemedical check-up vs 60% of the others. Among all monitored participants, 20 (66.7%) recorded at least 1 2-point or greater rise in MG-ADL score between consecutive assessments, and 11 of those (55%) reached out to their physician within a week of the increase. The authors wrote that "our data highlight the potential of remote monitoring to detect individual MG-related fluctuations reflecting disease status that may be missed in traditional care settings."

The findings came with clear caveats. The trial enrolled a small sample at a single academic center over a short observation window; the subgroup comparison was not pre-specified and carried no tests of statistical significance, and the cohort skewed female, consistent with early-onset disease but potentially underrepresenting late-onset MG. Participation also required a degree of digital literacy, and the absence of reimbursement pathways remained a barrier to routine adoption. Even so, the results pointed to a role for remote platforms in revealing the day-to-day course of a disease known for its variability and in directing added support toward the patients most likely to deteriorate.

References

1. Stein M, Mönch M, Herdick M, et al. Remote monitoring in myasthenia gravis: exploring symptom variability. Ann Clin Transl Neurol. 2026;13:1106-1117. doi:10.1002/acn3.70293
2. Pasnoor M, Miller-Wilson LA, Edwards Y, et al. Burden of disease in myasthenia gravis: a targeted literature review. J Neurol. 2026;273(5):288. doi:10.1007/s00415-026-13662-y